Petros Pharmaceuticals Stock (NASDAQ:PTPI)

Ownership Financials Chart

Previous Close

$0.01

52W Range

- - $5.75

50D Avg

$0.01

200D Avg

$0.02

Market Cap

$218.12K

Avg Vol (3M)

$141.05K

Beta

1.66

Div Yield

PTPI Company Profile

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Dec 02, 2020

Website

PTPI Performance

PTPI Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$5.11B	$5.82M	$5.99M
Operating Income	$-17.68B	$-13.62M	$-15.85M
Net Income	$-26.80B	$-8.16M	$-27.04M
EBITDA	$-12.05B	$-4.21M	$-13.73M
Basic EPS	$-333.88	$-6.35	$-13.06
Diluted EPS	$-333.88	$-6.35	$-13.06

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
XAGE	Longevity Health Holdings Inc.
IVF	INVO Fertility, Inc.
CELU	Celularity Inc.
SISI	Shineco, Inc.
SYRA	Syra Health Corp. Class A Common Stock
LIXT	Lixte Biotechnology Holdings, Inc.
CCM	Concord Medical Services Holdings Limited